BriaCell Therapeutics Corp.

Toronto Stock Exchange BCT.TO

BriaCell Therapeutics Corp. Gross Profit Margin for the year ending July 31, 2023

BriaCell Therapeutics Corp. Gross Profit Margin is NA for the year ending July 31, 2023. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

Toronto Stock Exchange: BCT.TO

BriaCell Therapeutics Corp.

CEO	Dr. William V. Williams M.D.
IPO Date	Aug. 13, 2012
Location	Canada
Headquarters	Bellevue Centre
Employees	16
Sector	Healthcare
Industries Biotechnology Clinical Trials Vaccines

Description

BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Key trends

Past 5 years